Loading…
Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.
Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.
Licenses bilastine to pharmaceutical partners in many countries, who sell it under their own brands, while Faes earns by supplying the active ingredient and from licence payments. A separate business sells prescription and generic medicines in Spain through pharmacies and hospitals.
In one line: A smaller, diversified generics/specialty pharma.
Moat: narrow (IP / patents, distribution). Bilastine licensing income is a durable niche, but broader portfolio faces generic competition.
Headquarters: Bilbao, Spain · Founded: 1933
Size Faes Farma (FAE.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 57th largest of 97 Spain companies the cockpit tracks. Shares closed at €4.88 on 6 Nov 2026.
Performance Over six months the shares gained 5.2%, against -10.6% for the median peer and +8.2% for the Spain market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 31.9% over the last twelve months (peer median +8.6%); the operating margin is 14.1% (peer median 15.2%).
Valuation It trades at 17.1× forward earnings against a peer median of 22.3× (7th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €697M | €610M | €494M | €451M | €439M |
| Revenue growth | — | +24% | +9% | +3% | — |
| Gross profit | €259M | €228M | €201M | €181M | €172M |
| EBITDA | €136M | €102M | €113M | €101M | €98.6M |
| Net income | €84.2M | €79.6M | €111M | €91.9M | €89.5M |
| Free cash flow | €61.6M | €62.4M | €81.7M | €5.21M | €31.8M |
| Capital expenditure | €25.6M | €23.6M | €39.6M | €102M | €80.9M |
| Total debt | n/a | €410M | €7.79M | €8.23M | €7.61M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Faes Farma FAE.MC | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% |
| Almirall ALM.MC | $2.74B | -2% | +24% | 8% | 30.6× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FAE.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.8% | -1.0% | 8th highest of 21 |
| 6-month return | +5.2% | -10.6% | 4th highest of 20 |
| Distance from 52-week high | -10.2% | -34.5% | 2nd highest of 21 |
| Revenue growth (TTM) | +31.9% | +8.6% | 5th highest of 19 |
| Operating margin | 14.1% | 15.2% | 9th lowest of 19 |
| Forward P/E | 17.1× | 22.3× | 7th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 3.1% | 6.7% | 7th least demanding of 14 |
| Growth delivered (Del g) | +9.9% | +10.8% | 7th lowest of 14 |
| Hurdle (Req g minus delivered) | -6.9 pp | -3.7 pp | 6th least demanding of 14 |
| ROIC minus cost of capital | +1.5 pp | +1.4 pp | 10th highest of 20 |
| EV / EBITDA | 13.2× | 15.9× | 4th cheapest of 9 |
| Net debt / EBITDA | 1.9× | -1.1× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |